| Chapter title |
Noncoding RNAs in Heart Failure
|
|---|---|
| Chapter number | 99 |
| Book title |
Heart Failure
|
| Published in |
Handbook of experimental pharmacology, January 2016
|
| DOI | 10.1007/164_2016_99 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-959658-7, 978-3-31-959659-4
|
| Authors |
Seema Dangwal, Katharina Schimmel, Ariana Foinquinos, Ke Xiao, Thomas Thum |
| Abstract |
Heart failure is a major contributor to the healthcare burden and mortality worldwide. Current treatment strategies are able to slow down the transition of healthy heart into the failing one; nevertheless better understanding of the complex genetic regulation of maladaptive remodeling in the failing heart is essential for new drug discovery. Noncoding RNAs are key epigenetic regulators of cardiac gene expression and thus significantly influence cardiac homeostasis and functions.In this chapter we will discuss characteristics of noncoding RNAs, especially miRNAs, long noncoding RNAs, and circular RNAs, and review recent evidences proving their profound involvement during different stages of heart failure progression. Several open questions still prevent the extensive use of noncoding RNA-modulating therapies in clinics; yet they are becoming an attractive target to define novel regulatory mechanisms in the heart. In-depth study of their interaction with gene networks will refine our current view of heart failure and revolutionize the drug development in coming years. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 19% |
| Student > Doctoral Student | 4 | 15% |
| Other | 2 | 8% |
| Student > Postgraduate | 2 | 8% |
| Professor > Associate Professor | 2 | 8% |
| Other | 3 | 12% |
| Unknown | 8 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 15% |
| Biochemistry, Genetics and Molecular Biology | 4 | 15% |
| Agricultural and Biological Sciences | 3 | 12% |
| Neuroscience | 2 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 11 | 42% |